These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27268470)

  • 1. Cardiovascular effects of anti-diabetes drugs.
    Younk LM; Lamos EM; Davis SN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1239-57. PubMed ID: 27268470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P; Acharya T
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the cardiovascular risk with non-insulin antidiabetic drugs.
    Athyros VG; Imprialos K; Stavropoulos K; Sahinidis A; Doumas M
    Expert Opin Drug Saf; 2019 Mar; 18(3):241-251. PubMed ID: 30810055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
    Lamos EM; Hedrington M; Davis SN
    Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.
    Chi C; Snaith J; Gunton JE
    Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.
    Flory JH; Ukena JK; Floyd JS
    Curr Atheroscler Rep; 2016 Dec; 18(12):79. PubMed ID: 27817160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S
    Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.
    Dai Y; Dai D; Mercanti F; Ding Z; Wang X; Mehta JL
    Acta Diabetol; 2013 Dec; 50(6):827-35. PubMed ID: 23824323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on DPP-4 inhibitors in the management of type 2 diabetes.
    Cahn A; Cernea S; Raz I
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):409-419. PubMed ID: 27809608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of type 2 diabetes: what's new in 2017?
    Scheen AJ
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1383-1394. PubMed ID: 28879786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.